According to a paper published by University of Alabama at Birmingham experts in the May 19.

Transplant centers. Sufferers enrolled in the trial were initial classified to be at a low or high risk of transplant rejection – high-risk patients included even more African-Americans and patients already sensitized to transplantation from a earlier transplant. Low-risk sufferers were assigned to receive either basiliximab or alemtuzumab randomly. High-risk sufferers were randomized into receiving antithymocyte globulin or alemtuzumab. Researchers then compared the efficacy and protection of basiliximab and antithymocyte globulin with that of alemtuzumab.Study Methods The first patient underwent randomization in October 2007, in February 2010 and follow-up of the last patient was completed. Each study included an interval of 4 weeks for screening, 24 weeks for correction, 12 weeks for evaluation, and 16 weeks or more of additional follow-up. Eligible patients were centrally allocated in a 1:1:1 ratio to receive peginesatide subcutaneously once every four weeks, starting at either 0.025 mg per kilogram or 0.04 mg per kilogram of body weight, or darbepoetin once 2 weeks every, beginning at 0.